Enchondroma

Distinguishing enchondroma from low-grade chondrosarcoma histologically is CHALLENGING. Key malignant features include: increased cellularity (hypercellularity), nuclear atypia (enlarged hyperchromatic nuclei), binucleate cells, myxoid degeneration, and permeation into surrounding bone. However, clinical and radiological correlation is ESSENTIAL - pain, axial location, and soft tissue mass are more reliable indicators of malignancy than subtle histological changes.

A classic examiner trap follows directly from the point above: the same histology means different things in different bones, and the hand is the great exception.

• Acral (hand and foot) enchondromas frequently look "atypical" - increased cellularity, plump and binucleate chondrocytes, and occasional myxoid change - yet they behave entirely benignly. True chondrosarcoma of the hand is rare.
• The danger is that a pathologist reading the slide without knowing it is a phalanx may over-call it chondrosarcoma, leading to unnecessarily radical surgery (even amputation) for a benign lesion. The identical cellularity and atypia in a pelvic or proximal-femoral cartilage tumour would genuinely indicate malignancy.
• Practical rules: always tell the pathologist the exact location; diagnose hand cartilage tumours by clinico-radiological correlation, not histology alone; and remember the converse - in the axial skeleton and long bones, even subtle atypia with a permeative growth pattern is concerning.
• The same forgiveness applies to the giant ("Takigawa") and protuberant hand variants, which remain benign despite a worrying size or appearance.

Exam point: in the hand/foot, cellular and atypical cartilage histology is acceptable and benign - do not let "worrying" histology drive radical surgery on a phalanx; inform the pathologist of the acral site and rely on clinico-radiological correlation, whereas the same features in an axial or proximal long-bone lesion signify chondrosarcoma.

Q: What is the most common location for enchondroma and what are its characteristic imaging features?

A: Most common in small bones of the hands and feet (50%), followed by proximal humerus and femur. Imaging: Well-defined lytic lesion in medullary cavity; Chondroid matrix calcification ("rings and arcs," "popcorn" pattern); Endosteal scalloping (less than 2/3 cortical thickness); No periosteal reaction or cortical destruction; Size usually less than 5cm. In long bones, located in metaphysis or metadiaphysis.

Q: How do you differentiate benign enchondroma from low-grade chondrosarcoma?

A: Features favoring malignancy: Size greater than 5cm; Location in axial skeleton or proximal limb girdle; Endosteal scalloping greater than 2/3 cortical thickness; Cortical destruction or soft tissue mass; Pain at rest (not related to pathological fracture); Interval growth on serial imaging; Periosteal reaction. MRI: Enchondroma has peripheral/septal enhancement only; Chondrosarcoma shows diffuse enhancement. When uncertain, biopsy may not differentiate - close surveillance or wide excision based on clinical concern.

Q: What is Ollier disease and Maffucci syndrome, and what is the malignancy risk?

A: Ollier disease: Multiple enchondromas (enchondromatosis), non-hereditary, asymmetric distribution. Maffucci syndrome: Multiple enchondromas + soft tissue hemangiomas. Malignancy risk: Ollier: commonly quoted 25-30% lifetime risk of chondrosarcoma (a large multicentre cohort found 40% overall and higher with axial/pelvic disease); Maffucci: lifelong risk approaching 100%, with additional vascular and visceral malignancies (e.g. ovarian, brain tumours). Both are driven by somatic mosaic IDH1/IDH2 mutations. Surveillance: clinical review with imaging of any new or symptomatic lesion; any pain or growth warrants investigation for malignant transformation.

Q: What is the standard treatment for solitary enchondroma in the hand?

A: Asymptomatic enchondroma: Observation with serial radiographs. Symptomatic (pain, pathological fracture risk) or post-fracture: Curettage and bone grafting. Technique: Allow fracture to heal first (4-6 weeks), then curettage through cortical window, thorough removal of cartilage, bone graft or cement. Recurrence rate: Less than 5%. Pathological fracture: May treat fracture first, then staged curettage, or combined if stable fixation achievable.

Q: What histological features differentiate enchondroma from chondrosarcoma?

A: Enchondroma: Hypocellular with small, uniform nuclei; Cells in lacunae with minimal atypia; No mitoses; Minimal myxoid change; Lobular architecture with peripheral enchondral ossification. Chondrosarcoma: Hypercellularity; Nuclear atypia, pleomorphism, binucleation; Mitotic figures (in higher grades); Myxoid matrix change; Permeation of surrounding bone trabeculae. Important: Histology alone may not differentiate Grade 1 chondrosarcoma from enchondroma - requires clinico-radiological correlation.